Adjuvant therapy with different bacillus Calmette-Guérin (BCG) preparations is a well-established guideline-endorsed treatment for nonmuscle invasive bladder cancer (NMIBC). Our observational study demonstrates equality between BCG and mitomycin C (MMC) treatment based on the oncological outcome. However, there were significant toxicity differences with higher rates in the BCG treatment group. The potential adverse effects of BCG in terms of a BCGitis are controversially discussed regarding their occurrence. As such, we sought to retrospectively evaluate the incidence in 106 consecutive patients. The BCG group demonstrated minor adverse effects in 78.4% and major adverse effects in 43.3%-partially coincident. Moreover, the parallel MMC group showed in 34.7% respectively 1.4% adverse events-as expected distinctly lower. In the context of this clinical discussion, we refer to alternative treatment concepts. Our data show a high clinical relevance of the patient's primary comorbidity.
Der Urologe. Ausg. A. 2018 Mar 02 [Epub ahead of print]
W-D U Böhm, R Koch, S Wenzel, M P Wirth, M Toma
Akademische Lehrpraxis für Urologie, Ärztehaus am Krankenhaus St. Joseph-Stift Dresden, Dresden, Deutschland. ., Institut für Biometrie und Medizinische Statistik, Technische Universität Dresden, Dresden, Deutschland., Klinik und Poliklinik für Urologie, Universitätsklinikum Dresden, Dresden, Deutschland., Institut für Pathologie, Universitätsklinikum Bonn, Bonn, Deutschland.